JP2022512754A5 - - Google Patents

Info

Publication number
JP2022512754A5
JP2022512754A5 JP2021521306A JP2021521306A JP2022512754A5 JP 2022512754 A5 JP2022512754 A5 JP 2022512754A5 JP 2021521306 A JP2021521306 A JP 2021521306A JP 2021521306 A JP2021521306 A JP 2021521306A JP 2022512754 A5 JP2022512754 A5 JP 2022512754A5
Authority
JP
Japan
Prior art keywords
fusion protein
seq
virus
acid sequence
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021521306A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512754A (ja
Filing date
Publication date
Priority claimed from GBGB1816873.2A external-priority patent/GB201816873D0/en
Application filed filed Critical
Publication of JP2022512754A publication Critical patent/JP2022512754A/ja
Publication of JP2022512754A5 publication Critical patent/JP2022512754A5/ja
Pending legal-status Critical Current

Links

JP2021521306A 2018-10-17 2019-10-16 融合タンパク質 Pending JP2022512754A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816873.2 2018-10-17
GBGB1816873.2A GB201816873D0 (en) 2018-10-17 2018-10-17 Fusion protein
PCT/GB2019/052945 WO2020079427A1 (en) 2018-10-17 2019-10-16 Fusion protein

Publications (2)

Publication Number Publication Date
JP2022512754A JP2022512754A (ja) 2022-02-07
JP2022512754A5 true JP2022512754A5 (https=) 2022-09-26

Family

ID=64397455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521306A Pending JP2022512754A (ja) 2018-10-17 2019-10-16 融合タンパク質

Country Status (11)

Country Link
US (1) US20210386850A1 (https=)
EP (1) EP3866840A1 (https=)
JP (1) JP2022512754A (https=)
KR (1) KR20210114379A (https=)
CN (1) CN113164575A (https=)
AU (1) AU2019363172A1 (https=)
BR (1) BR112021007487A2 (https=)
CA (1) CA3116623A1 (https=)
GB (1) GB201816873D0 (https=)
WO (1) WO2020079427A1 (https=)
ZA (1) ZA202102533B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
CN118414349A (zh) * 2021-12-20 2024-07-30 硕腾服务有限责任公司 用于在细胞膜上表达抗原的组合物和方法
CN116240175B (zh) * 2023-02-28 2024-02-23 武汉科技大学 一种嵌合抗hiv广谱中和抗体外泌体的制备方法以及在抗hiv感染中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2378661A1 (en) * 1999-07-09 2001-01-18 Alexander C. Schmidt Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
BRPI0414443A (pt) * 2003-09-17 2006-11-21 Univ Duke imunógenos consensuais/ancestrais
MX2008000985A (es) * 2005-07-21 2008-04-07 Abbott Lab Expresion de gen multiple que incluye construcciones y metodos sorf (cuadro de lectura abierta simple) con poliproteinas, pro-proteinas y proteolisis.
FR2938840B1 (fr) * 2008-11-21 2010-12-17 Centre Nat Rech Scient Proteines mutantes de la proteine f de piv-5 et de piv-2
FR2938841B1 (fr) * 2008-11-21 2010-12-17 Centre Nat Rech Scient Proteines mutantes de la proteine f de piv-5 et de piv-2
EP2583974B1 (en) * 2011-10-21 2017-04-26 Technische Universität Dresden Pseudotyping of foamy viruses
ES2728248T3 (es) * 2012-01-24 2019-10-23 Univ Georgia Vacunas basadas en el virus paragripal 5
DK3247388T3 (da) * 2015-01-20 2025-12-22 Us Health Rekombinant human/bovin parainfluenzavirus 3 (b/hpiv3), der udtrykker et kimærisk rsv/bpiv3 f-protein, og anvendelser deraf
US10316295B2 (en) * 2015-12-17 2019-06-11 The Penn State Research Foundation Paramyxovirus virus-like particles as protein delivery vehicles

Similar Documents

Publication Publication Date Title
JP2022512754A5 (https=)
Nagai Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding
Nagai et al. Paramyxovirus reverse genetics is coming of age
EP2034014A1 (en) Therapeutic agent for alzheimer's disease
US20100167341A1 (en) Novel protein expression system
US20120087940A1 (en) Vector for treating alzheimer's disease
JPWO2008007581A1 (ja) 非複製型パラミクソウイルス科ウイルスベクター
JP6927883B2 (ja) 改良されたパラミクソウイルスベクター
EP2123755A1 (en) Attenuated minus-stranded rna virus
EP2363472B1 (en) Method for enhancing expression of recombinant protein
JP2020522249A5 (https=)
JP6783794B2 (ja) ベクターとしてセンダイウイルスを用いた抗結核菌ワクチン
Zhu et al. Reverse genetics of rabies virus: new strategies to attenuate virus virulence for vaccine development
JP4791651B2 (ja) 外来遺伝子導入用パラミクソウイルスベクター
RU2021113533A (ru) Слитый белок
WO2018092887A1 (ja) 非感染性パラミクソウイルス粒子を用いた感染症ワクチン
CN112135908A (zh) 选择性cd8阳性t细胞诱导疫苗抗原
KR20260059692A (ko) 고증식성 파라믹소바이러스 변이체 및 이의 용도
RU2021111003A (ru) Рекомбинантный живой вакцинный штамм респираторно-синцитиального вируса (рсв) и способ его получения
CN101243179A (zh) 制备抗体的方法
CA3172492A1 (en) Influenza virus-like particles (vlps)
JP2005034105A (ja) 原形質膜粒子の放出を促進する方法
SITES Facultad de Ciencias Departamento de Biología Molecular
Daniel Influenza virus non-structural protein NS1 cooperatively binds virus-specific (+)-strand RNA sequences
HK40011813A (en) Infectious disease vaccine using non-infectious paramyxovirus particle